Navigation Links
MS patients report greater treatment satisfaction with TYSABRI
Date:5/28/2009

Atlanta, Ga. May 28, 2009 Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced interim results from an ongoing, one-year longitudinal health-outcomes study in which patients reported significantly higher levels of treatment satisfaction after three infusions with TYSABRI (natalizumab) when compared to multiple sclerosis (MS) therapies used previously. The findings from the study, which were reported by patients on therapy, further demonstrate the benefits of TYSABRI in treating MS and are helping to redefine successful treatment of the disease. The study, which was performed in conjunction with HealthCore Inc., a health-outcomes research company, is being presented in a poster today during the 23rd Annual Meeting of the Consortium of Multiple Sclerosis Centers.

"The patients in this study reported significantly greater satisfaction with TYSABRI when compared to their previous MS treatments, which makes these data even more compelling for patients who may not be satisfied with their current treatment," said William Stuart, M.D., medical director of the Multiple Sclerosis Center of Atlanta. "When coupled with previously reported data from this ongoing study that showed overall improvement in quality of life measures, we have a clearer picture of the real-world impact of TYSABRI on MS patients' lives. The success of TYSABRI over the past three years should be an encouragement to move this drug to the forefront of treatment options in many select MS patients."

About the Study

This ongoing study, which is the first attempt to evaluate patient experiences with TYSABRI in usual-care settings, will continue to assess health outcomes from the patients' perspectives, with subsequent data collections, after the sixth and 12th TYSABRI infusions. A total of 1,275 patients were enrolled in the study. Of these patients, 702 completed the third infusion assessment at the time of the analysis. Of the 1,275, there were 224 patients who were still being contacted or had not yet reached their third infusion. Of the initial 1,275; 43 chose to no longer participate in the study, 60 had already received a fourth infusion, 53 were unable to be contacted and 193 discontinued or had never started TYSABRI treatment.

These patient-reported outcomes paint a broad picture of MS patients' ongoing treatment experience, which helps us to measure the effectiveness of MS treatments and expand our understanding of their everyday impact. A majority of the patients in the study are female (78.4%) with a mean age of 45.3 years and mean disease duration of 10 years. Almost all (97%) patients had used at least one MS drug prior to receiving TYSABRI.

Patient satisfaction with treatment was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM) with higher scores indicating higher satisfaction.

In the study, patients' attitudes towards MS drugs, with respect to effectiveness, convenience and overall satisfaction, at baseline (n=681) were compared to their attitudes to the same measures after three TYSABRI infusions.

As compared to other MS drugs, patients reported statistically significant higher levels of satisfaction after three infusions of TYSABRI with respect to:

  • effectiveness of treatment (baseline 43.9 vs. 63.5 at the third infusion; p< 0.001);
  • convenience of treatment (baseline 58.9 vs. 80.0 at the third infusion; p< 0.001); and
  • global satisfaction (baseline 61.5 vs. 73.8 at the third infusion; p< 0.001).

The poster Treatment Satisfaction with Natalizumab in Multiple Sclerosis Patients (S63) will be available for viewing begining on Thursday, May 28, 2009, 8:00 a.m EDT.


'/>"/>

Contact: Shannon Altimari; Biogen Idec
617-914-6524
GCI Health
Source:Eurekalert

Related medicine news :

1. New Video Series Spotlights Role of Biomedical Engineers in Caring for Total Artificial Heart Patients
2. HeartMath Launches a Certification Program for Health Professionals that Targets Patients' Stress and Anxiety
3. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
4. Dementia drugs may put some patients at risk, Queens study shows
5. New Survey Highlights Growing Concern About Risk of Infection in Cancer Patients and Emerging Antibiotic Resistance
6. New Non-Surgical Laser Treatment Helps Patients Live Pain Free
7. NEJM study finds drug-eluting stents more effective than bare-metal stents in heart attack patients
8. Medical Marketing DVD Helps Doctors and Hospitals Win Patients Despite The Recession
9. Medeguide and Patients Beyond Borders Collaborate to Feature Global Healthcare Options Online
10. A first choice of renal function tests in hepatectomy patients
11. IBM Helps Ling Tung University Build System to Monitor and Analyze Patients Health at Home
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology: